Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2017 | 12-2016 | 12-2015 | |
| Sales | 449 | 0 | 0 |
| Gross Profit | 449 | N/A | N/A |
| Operating Expenses | 6,004 | 0 | 0 |
| Operating Income | -5,555 | N/A | N/A |
| Other Income | 81 | 0 | 0 |
| Pre-tax Income | -5,474 | 0 | 0 |
| Net Income Continuous | -5,474 | N/A | N/A |
| Net Income | $-5,474 | $N/A | $N/A |
| EPS Basic Total Ops | -77.70 | N/A | N/A |
| EPS Basic Continuous Ops | -77.64 | N/A | N/A |
| EPS Diluted Total Ops | -77.70 | N/A | N/A |
| EPS Diluted Continuous Ops | -77.64 | N/A | N/A |
| EBITDA(a) | $-5,506 | $N/A | $N/A |